Peridural Anesthesia and Cancer-Related Survival after Surgery for Pancreatic Cancer-A Retrospective Cohort Study.
oncological outcome
pancreatic adenocarcinoma
recurrence
staging
Journal
Clinics and practice
ISSN: 2039-7275
Titre abrégé: Clin Pract
Pays: Switzerland
ID NLM: 101563282
Informations de publication
Date de publication:
18 Aug 2021
18 Aug 2021
Historique:
received:
07
05
2021
revised:
02
08
2021
accepted:
04
08
2021
entrez:
27
8
2021
pubmed:
28
8
2021
medline:
28
8
2021
Statut:
epublish
Résumé
In patients with prostatic and breast cancer the application of peridural anesthesia (PDA) showed a beneficial effect on prognosis. This was explained by reduced requirements for general anesthetics and perioperative opioids as well as a lower perioperative stress level. The impact of PDA in patients with more aggressive types of cancer has not been completely elucidated. Here, we analyzed the prognostic influence of PDA on overall survival after surgery as primary in patients that underwent radical resection of pancreatic adenocarcinoma. Records of 98 consecutive patients were reviewed. In 70 of these cases PDA was applied. Patient characteristics such as demographics, TNM stage, and operative data were retrospectively collected from medical records and analyzed. Survival data were analyzed by Cox's proportional hazard regression model. Overall, no significant prognostic influence of PDA on recurrence or overall survival ( The observation of longer survival associated with PDA in our subgroup of patients with better-differentiated pancreatic carcinomas is in line with previous reports on various other less aggressive tumor entities. Our results indicate that PDA might improve the oncological outcome of patients with pancreatic adenocarcinoma.
Sections du résumé
BACKGROUND
BACKGROUND
In patients with prostatic and breast cancer the application of peridural anesthesia (PDA) showed a beneficial effect on prognosis. This was explained by reduced requirements for general anesthetics and perioperative opioids as well as a lower perioperative stress level. The impact of PDA in patients with more aggressive types of cancer has not been completely elucidated. Here, we analyzed the prognostic influence of PDA on overall survival after surgery as primary in patients that underwent radical resection of pancreatic adenocarcinoma.
METHODS
METHODS
Records of 98 consecutive patients were reviewed. In 70 of these cases PDA was applied. Patient characteristics such as demographics, TNM stage, and operative data were retrospectively collected from medical records and analyzed. Survival data were analyzed by Cox's proportional hazard regression model.
RESULTS
RESULTS
Overall, no significant prognostic influence of PDA on recurrence or overall survival (
CONCLUSION
CONCLUSIONS
The observation of longer survival associated with PDA in our subgroup of patients with better-differentiated pancreatic carcinomas is in line with previous reports on various other less aggressive tumor entities. Our results indicate that PDA might improve the oncological outcome of patients with pancreatic adenocarcinoma.
Identifiants
pubmed: 34449573
pii: clinpract11030070
doi: 10.3390/clinpract11030070
pmc: PMC8395495
doi:
Types de publication
Journal Article
Langues
eng
Pagination
532-542Références
Anesth Analg. 2008 May;106(5):1562-5, table of contents
pubmed: 18420877
Crit Rev Oncol Hematol. 2006 Jun;58(3):231-41
pubmed: 16725343
Med Sci Monit. 2016 Jul 08;22:2379-85
pubmed: 27386842
J Am Stat Assoc. 2014 Jul 1;109(507):991-1007
pubmed: 25346558
Am J Surg. 1996 Jan;171(1):118-24; discussion 124-5
pubmed: 8554125
Anesthesiology. 2006 Oct;105(4):660-4
pubmed: 17006061
Cancer Metastasis Rev. 2017 Mar;36(1):159-177
pubmed: 27866303
Anesthesiology. 2012 Apr;116(4):797-806
pubmed: 22273991
Oncogene. 2008 Oct 6;27(45):5894-903
pubmed: 18836470
Ann Fr Anesth Reanim. 2013 May;32(5):e81-8
pubmed: 23618609
Lancet. 2008 Aug 16;372(9638):562-9
pubmed: 18692893
PLoS One. 2014 Dec 30;9(12):e114667
pubmed: 25548913
Reg Anesth Pain Med. 2014 May-Jun;39(3):200-7
pubmed: 24686324
BMJ. 2011 Mar 29;342:d1491
pubmed: 21447587
Br J Anaesth. 2012 Aug;109(2):185-90
pubmed: 22525284
Pharmacol Res. 2015 May-Jun;95-96:126-31
pubmed: 25839130
Clin Orthop Relat Res. 2014 May;472(5):1434-41
pubmed: 24081665
Pain Manag. 2015 Sep;5(5):387-95
pubmed: 26250850
BMC Anesthesiol. 2016 Mar 12;16:16
pubmed: 26971194
Anesth Analg. 2001 Oct;93(4):853-8
pubmed: 11574345
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
pubmed: 21296855
Anesth Analg. 2008 Jul;107(1):325-32
pubmed: 18635504
Anesthesiology. 2007 Aug;107(2):354; author reply 354-5
pubmed: 17667583
Oncotarget. 2017 Mar 30;8(37):62658-62665
pubmed: 28977978
Can J Anaesth. 2016 Feb;63(2):184-92
pubmed: 26497721
Eur J Cancer Prev. 2008 Jun;17(3):269-72
pubmed: 18414199
Front Genet. 2019 Jul 18;10:624
pubmed: 31379917
Clin Exp Metastasis. 2018 Apr;35(4):347-358
pubmed: 28894976
Ann Surg. 2008 Mar;247(3):456-62
pubmed: 18376190
BMJ. 2000 Dec 16;321(7275):1493
pubmed: 11118174
J Transl Med. 2018 Jan 18;16(1):8
pubmed: 29347949
Anesthesiology. 2008 Aug;109(2):180-7
pubmed: 18648226
Anesthesiology. 2015 Feb;122(2):317-24
pubmed: 25305092
Medicine (Baltimore). 2017 Mar;96(10):e6137
pubmed: 28272202
Rev Esp Anestesiol Reanim. 2015 Dec;62(10):570-5
pubmed: 26026503
Anesthesiology. 2010 Jul;113(1):27-34
pubmed: 20508494
Can J Anaesth. 2016 May;63(5):584-95
pubmed: 26850064
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Br J Anaesth. 2019 Aug;123(2):135-150
pubmed: 31255291
Surgery. 2000 Mar;127(3):329-36
pubmed: 10715990
Anesthesiology. 2010 Sep;113(3):570-6
pubmed: 20683253
BMC Anesthesiol. 2018 Nov 3;18(1):157
pubmed: 30390636
BMJ. 1999 Aug 28;319(7209):530-1
pubmed: 10463878
Can J Anaesth. 2010 Feb;57(2):107-12
pubmed: 19911247
Urol Oncol. 2019 Dec;37(12):845-852
pubmed: 31526652